Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in Taiwan
Upadacitinib 30 mg was the most cost-effective option for moderate-to-severe atopic dermatitis in Taiwan, but its high budget impact underscores the need for strategic pricing and reimbursement policies to ensure long-term affordability and access.
Authors
- Yen Hsiang Wang
- R. Yang
- David Bin-Chia Wu (ORCID: https://orcid.org/0009-0008-4759-7955)
- Hsiao-Hsiao Tan
- Toby Kai-Bo Shen
- John Tayu Lee
- Valerie Tzu-Ning Liu
Institutions
- National University of Singapore (SG)
- National Taiwan University (TW)
- National University Health System (SG)
- The Korean Atopic Dermatitis Association (KR)
- Imperial College London (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1080/13696998.2026.2612867
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00